Hatchtech completes treatment phase of 2b clinical trial of new-generation head lice treatment
This Phase 2b trial is evaluating the efficacy, safety and tolerability of two dose levels of a single application of DeOvo™ compared to vehicle. The trial consists of treating 132 healthy subjects with head lice infestation, 2 years of age and older, in two study centers in the United States.
Hatchtech’s proprietary product DeOvo™ is a topical formulation of a known metalloprotease inhibitor which targets proteases that are key to biological processes involved in insect hatch and survival.
Hatchtech Chairman Dr Paul Kelly commented: “We continue to be encouraged by Hatchtech’s progress with its next generation head lice product DeOvo™ in line with our business objectives. The recruitment and treatment of subjects in this study has been achieved and we look forward to receiving results of the study later this year as planned.”
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.